Augnition Labs joins the Precision Aging Network’s Mindcrowd 2.0

July 21, 2022 – Augnition Labs today announces the inclusion of their Cognitive Test Suite, Augmem™ as part of the University of Arizona Precision Aging Network’s Mindcrowd 2.0.

Funded through a $60M five-year grant from the National Institutes of Health, the Precision Aging Network (PAN) applies principles of precision medicine to diseases of the aging brain and neurological system. Project Lead, Professor at the University of Arizona, Carol Barnes notes, “We all need a prescription that fits us individually if we are to optimize our cognitive health.”

Dementia affects over 55 million people globally with patient numbers predicted to double every 20 years. By understanding “What is a normative aging brain?” Barnes hopes to better understand dementia, and support the development of effective therapies for treatment and prevention.

The network will recruit 350,000 adult participants from across its different sites and collect demographic, lifestyle and health information, as well as cognition data. Augmem’s three digital tests are being included to provide highly precise testing of memory performance through brain-game style tasks. Their incorporation will help further PAN’s understanding of the impact of age on different parts of the brain, particularly the hippocampus.

Based on close to two decades of research by Dr. Michael Yassa, the Augmem™ test suite provides precise and accurate tracking of memory performance using pattern separation tasks. A reduction in pattern separation capabilities, a skill required to create, store and retain unique memories of similar experiences, is an early indicator of cognitive decline. By harnessing this knowledge, Augmem is sensitive to even the most subtle shifts in cognition.


Dr. Yassa believes inclusion in PAN’s Mindcrowd is great for Augnition because “We need to know how different aspects of memory are impacted by age. Remembering what happened, when it happened and where it happened is how we construct our autobiographical memories and Augmem assesses these three components in detail.”


Following Mindcrowd 2.0’s digital data gathering phase, a subset of participants will be invited to take part in in-person studies at one of four sites: University of Arizona in Tucson, Emory University in Atlanta, Johns Hopkins University in Baltimore and the University of Miami in Coral Gables, Florida. This will allow access to biomarker data to further validate the Augmem platform.


About Augnition Labs

Augnition Labs was launched in 2020 with the mission of developing  AI-powered digital assessment and monitoring solutions for early detection of cognitive decline. Augnition’s lead technology, the Augmem™ platform, provides precise and accurate tracking of memory performance. Our technology is a world leader in earlier detection and monitoring of memory loss, supporting better outcomes, lower costs and prolonged quality of life.

Marco Peters, Ph.D.

Co-Founder and Scientific Advisor

Dr. Peters has over 20 years of experience in translational research, target discovery, and small molecule discovery for CNS indications. He built and managed small and large research teams, and his work has contributed to the discovery, progression, and clinical development of small molecule therapeutics for the treatment of multiple neurological indications including stroke, Alzheimer’s Disease, Parkinson’s disease, pain, and schizophrenia. He currently serves as vice president and head of translational science at Longboard Pharmaceuticals. Peters built the departments of Neurobiology and Behavioral Pharmacology, and managed target identification, in vivo pharmacology, and lead optimization at Dart Neuroscience. His work contributed to the advancement of multiple compounds into clinical development, and led to a broad intellectual property portfolio focused on enhancement of brain plasticity and cognitive function. Peters has a M.Sc. in Biochemistry from the Freie Universität Berlin, Germany and a PhD in Neuroscience from the University of London, UK. He conducted postdoctoral work on Alzheimer’s disease with Tetsuyuki Maruyama at Merck Sharp & Dohme (UK).